Cargando…
A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma
The transcription factor MycN is the prototypical neuroblastoma oncogene and a potential therapeutic target. However, its strong expression caused by gene amplification in about 30% of neuroblastoma patients is a considerable obstacle to the development of therapeutic approaches aiming at eliminatin...
Autores principales: | Sottile, Francesco, Gnemmi, Ilaria, Cantilena, Sandra, D'Acunto, Walter C., Sala, Arturo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388183/ https://www.ncbi.nlm.nih.gov/pubmed/22619121 |
Ejemplares similares
-
Physical Interaction between MYCN Oncogene and Polycomb Repressive Complex 2 (PRC2) in Neuroblastoma: FUNCTIONAL AND THERAPEUTIC IMPLICATIONS
por: Corvetta, Daisy, et al.
Publicado: (2013) -
Addiction of MYCN Amplified Tumours to B-MYB Underscores a Reciprocal Regulatory Loop
por: Gualdrini, Francesco, et al.
Publicado: (2010) -
Identification and Pharmacological Inactivation of the MYCN Gene Network as a Therapeutic Strategy for Neuroblastic Tumor Cells
por: Chayka, Olesya, et al.
Publicado: (2015) -
MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019) -
Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence
por: Taschner-Mandl, Sabine, et al.
Publicado: (2015)